Five dogs with mucopolysaccharidosis I, a model of human Hurler/Scheie syndrome, were transplanted with marrow from phenotypically normal littermates at 5 mo of age. At 3 and 9 mo posttransplantation, biopsies of cerebral cortex, liver, and cerebrospinal fluid were obtained. The a-L-iduronidase levels in these tissues were 0.8-7.4, 26-45, and 6.3-14.9% of the paired donor tissues, respectively. Although iduronidase was present in relatively low levels in the recipients' brains and cerebrospinal fluid at both biopsy times, reduction in brain glycosaminoglycan (GAG) was comparable to that observed in liver. Ultrastructural studies of cells within the transplanted dogs' brains showed less lysosomal distension and storage product than in affected, nontransplanted, littermate controls. The most marked clearing of stored GAG was in cells surrounding blood vessels, but decreased lysosomal storage in neurons and glial cells was also observed. Urinary GAG excretion also decreased to near normal levels by 5 mo posttransplantation.
Introduction
The initial rationale for attempting transplantation therapy in inherited enzyme deficiency diseases has been supported by recent reports of clinical improvement in patients after transplantation, usually of bone marrow. Whether due to direct replacement of cells within various tissues, enzyme leakage or secretion from transplanted cells with subsequent cellular uptake, or by clearance of circulating substrate, extraneural sites such as liver, spleen, cornea, and joints have been shown to benefit. The number of lysosomal storage diseases in which hematopoietic stem cell transplantation has been attempted is increasing and now includes Hurler (1), Hunter (2) , Sanfilippo B (3), Morquio (4) , and Maroteaux-Lamy (5) syndromes, Fabry's disease (6) , Niemann-Pick disease (6) , metachromatic leukodystrophy (7), adrenoleukodystrophy (8), Gaucher's disease (9), and murine Krabbe's disease (10) . The degree ofclinical improvement varies, those diseases characterized mainly by visceral storage, without neural involvement, generally being more ammenable to treatment than those diseases with progressive neurodegeneration. The critical question as to what extent hematopoietic cell transplantation can be expected to lead to improvement in those diseases with central nervous system (CNS) involvement has yet to be fully answered. Clearly, the blood-brain barrier represents a significant impediment to enzyme transfer within intact cells or free in the blood.
A canine animal model of mucopolysaccharidosis I (MPS I),' caused by deficiency of the lysosomal enzyme a-L-iduronidase (EC 3.2.1.76, herein referred to as iduronidase), has been described in a family of Plott hounds (11, 12) . Affected (14) . The lesions within the CNS ofboth species are also very similar, each having glial and neuronal storage of DS and HS and secondary accumulations of GM3, GM2, and GD3 gangliosides (15) . Development of lamellar zebra bodies within lysosomes of affected neurons and other cells is seen in both species ( 12) .
When available, animal models of human disease provide the opportunity to study potential treatment protocols in a manner not possible with human patients. The canine MPS I model was used to evaluate the effects of bone marrow transplantation with an emphasis on the effects within the CNS.
Methods
Five dogs affected with MPS I were transplanted at 5 mo of age with bone marrow from a nonaffected littermate. In three ofthe five transplants the donor was presumed by its enzyme level to be a heterozygote, but their status has not been confirmed by breeding.
Recipients were given total body irradiation (TBI) of 7.5-8.5 Biopsies of liver and cerebral cortex were obtained from recipients, donors, and littermate affected, nontransplanted controls, at 3 and 9 mo posttransplantation. Cerebrospinal fluid (CSF) was obtained concurrently and assayed for GAG content, iduronidase activity, and examined cytologically with Wright-Giemsa and Alcian blue stains.
Tissue and CSF iduronidase was measured by a fluorimetric assay as previously described (16) . Briefly, after homogenization and sonication at 4VC, the tissue homogenate protein concentration was determined by the method of Lowry (17) . 40 Mg of protein was incubated for 1 h at 370C with 25 Ml of0.05 mM 4-methylumbelliferyl-iduronide in a 0.4 M formate buffer (pH 3.5). After the addition of 1 ml carbonate-glycine buffer (pH 9.85) liberated 4-methylumbelliferone was read on a fluorimeter and compared with a I-nmol 4 MU standard. Final results were expressed as nanomoles substrate hydrolyzed per milligram protein per hour ofincubation (nmol/mg per h). The CSF assay was identical except that the incubation was 5 h at 25°C and 50 Ml of sample was used. All assays were run in triplicate and included both specimen and reagent blanks, which were subtracted to obtain the final result. Before analysis, tissues were stored at -80°C for a maximum of 1 wk.
Glycosaminoglycan levels in tissues and CSF were measured by previously published techniques (18) and expressed as micrograms uronic acid content per 100 Mg of lipid-free dry weight (% LFDW) for tissues and micrograms uronic acid per milliliter for CSF. Urine was collected before transplantation (two recipients) and after transplantation (all recipients) for GAG analysis; results were expressed as micrograms uronic acid per milligrams creatinine.
In addition to tissue frozen for biochemical analysis, a portion of each biopsy was minced immediately after collection in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). Tissues were postfixed in 1% osmium tetroxide for I h and subsequently washed, dehydrated, and embedded in Epon 812. I-,um sections were stained with toluidine blue; thin sectioning was followed by routine staining with uranyl acetate and lead citrate and the sections were viewed on a Philips 201 electron microscope. 10 neuronal profiles from one transplanted dog and its nontransplanted littermate control were photographed and the volume fraction of lysosomes was determined using point counting volumetry (19) . Two-sample paired t tests were computed to determine whether biochemical changes seen after transplantation represented statistically significant differences between treated dogs and the normal or affected controls. Clinical signs of MPS I, which have developed in the affected controls, have essentially been eliminated in the transplanted dogs. Most notable in the surviving recipients are decreases in corneal clouding and joint instability, which have caused loss of visual acuity, lameness, and exercise intolerance in the nontransplanted dogs. Mild corneal neovascularization ofunknown etiology, which responded to topical corticosteroid treatment, was seen in the recipients. In all recipients the levels of urinary GAG have approached normal values after initial increases in GAG excretion occurred in two dogs (Fig. 1) . Detailed reports of clinical, radiographic, and echocardiographic studies will be published elsewhere. Table I presents tissue and CSF activities of iduronidase at 3 and 9 mo posttransplantation. The two dogs that died before the 3-mo biopsy had tissues collected at necropsy for biochemical analyses. Both dogs had detectable iduronidase activity in brain, liver, and CSF, but are not included in Table I due to their illness at the time oftissue collection. Enzyme was not detectable in the liver, brain, or CSF of nontransplanted, affected dogs at either biopsy time. There appeared to be a correlation between the enzyme activity of the donor animal (litter 1, probable heterozygote; litters 2 and 3, normal) and the levels attained in the recipients.
Results
Recipients' liver, at 3 mo posttransplantation, contained 32-45% and, at 9 mo, 26-38% of donor activity of iduronidase. Cerebral cortical tissues of all recipients contained small, but consistently detectable amounts of iduronidase. Individual recipient brain tissues contained between 0.8 and 7.4% ofthe concurrent donors activity, with the average values at 3 and 9 mo posttransplantation being 2.8 and 1.0%, respectively. Iduronidase was present in relatively higher concentrations in CSF of the transplanted dogs than in their brain tissue. Between 6.3 and 14.9% of donor iduronidase was found in the recipient's samples; the average 3-and 9-mo posttransplantation activities were 10.8 and 7.2% of donor activities, respectively.
In each recipient a significant reduction in GAG storage was seen when compared with the concurrent level in the affected littermate control. Brain tissue in the recipients also had statistically significant reductions in GAG by 3 mo posttransplantation and remained nearly constant throughout the period of study in the donor animals and recipients (Table II) . Compared with the nontransplanted MPS I dogs, the recipient brains had from 30 to 82% reduction in GAG levels. The mean brain GAG concentration in the recipients at 3 and 9 mo (0.13 and 0.15% LFDW) both represented statistically significant decreases (P < 0.05) in GAG storage compared with untreated affected dogs and were close to levels in the donors. In one of the nontransplanted dogs the (Fig. 7) . Marked distortion of lysosomes in CNS macrophages (Fig. 8) , common in the affected control dogs, was not seen in any of the transplanted dogs.
Preliminary morphometric analysis of neuronal lysosomes from one transplanted and one control dog supported the initial subjective contention that significant differences existed 9 mo after transplantation. The volume fraction (+SE) of lysosomes from the affected, nontransplanted dog (0.069±0.015) was significantly greater (P < 0.05) than that of its littermate, transplanted dog (0.027±0.003).
Discussion
Since the first attempt at treatment of Hurler syndrome in children by bone marrow transplantation, the concern whether intellectual improvement would Cerebral neuron cytoplasm from another nontransplanted MPS I dog at 8 mo of age. The degree of lysosomal change is similar to that in Fig. 4 except that early zebra body formation is only present in two lysosomes (arrows). Bar, 1 gm.
--*5. neurodegenerative disorders) has been repeatedly expressed (20) (21) (22) . Whereas the canine model of MPS I has afforded the opportunity to examine biochemical and ultrastructural changes in the CNS after transplantation, unfortunately there is no way of assessing mental development in dogs. Nonetheless, findings in dogs may provide information relevant to the human situation regarding the ability oftransplanted cells or enzyme to cross the blood-brain banier and affect some degree of metabolic correction within the CNS.
Compared with donor levels, the activity of recipient brain iduronidase was quite small, although consistently detectable. The concentrations found in transplant recipients (0. (12, 24, 25) . While GAG storage can be identified in various CNS cells in MPS I, the exact defect leading to mental retardation is not known. That iduronidase deficiency without CNS GAG accumulation (MPS IS) results in no loss of mental capabilities implies that disruption of neuronal function related to GAG accumulation may in some way be involved. The development of hydrocephalus and meningeal thickening may also be important factors involved with mental retardation. Therefore, therapy that reduces these nonneuronal conditions might be beneficial regardless of whether the effect on neuronal function is direct or indirect.
The concentration and composition of sulfated GAG in the brain and liver of normal dogs and humans are very similar (12, 26 (31) . Human hexosaminidase has been shown to cross the blood-brain barrier after osmotic modification in rats and to then localize in a subcellular organelle in the rat's brain (32) . Whereas it is generally accepted that bone marrow origin cells are responsible for continued replacement of macrophages in tissues such as lung and liver (33, 34) , the origin and turnover of CNS phagocytes is less well understood. There is evidence that murine brain contains a resident population of phagocytic cells that are of bone marrow origin (35, 36) . To what extent there is postembryologic renewal of cells within the CNS from the marrow is not well established. It has been shown, however, that circumstances such as injury or inflammation (possibly radiation) will cause blood-borne cells to enter the CNS in significant numbers (37). More relevant to the bone marrow transplantation situation are the findings of Ting et al. (38) , who showed that murine radiation-induced chimeras have cells containing Ia antigens of donor origin within their brains. This study concluded the Ia' brain cells turnover and are replaced by cells of bone marrow origin. If similar human and canine cells exist, and are capable of entering the CNS of radiation induced bone marrow chimeras, the potential for some degree of CNS improvement exists in neurodegenerative disorders. Donor cells containing a deficient enzyme may cause decreased lysosomal storage in recipient cells either by transfer of enzyme or by creating a concentration gradient of the storage product, essentially causing transfer of substrate.
Despite failures to affect nervous system improvement after bone marrow transplantation in several storage diseases (metachromatic leukodystrophy [39] , adrenoleukodystrophy [8] , murine Krabbe's disease [10] , murine Niemann-Pick disease [40] ), as well as lack of CNS improvement in a chimeric calf with mannosidosis (41), the case is not closed. Encouraging evidence that transplantation therapy may have beneficial neurologic effects in some diseases continues to be found. One boy with metachromatic leukodystrophy transplanted with his normal sister's marrow has shown developmental progress 33 mo after the procedure (7). Three MPS IH patients have also improved after bone marrow transplantation in that computerized tomography and magnetic resonance imaging have shown no progression ofcharacteristic lesions in their brains (42) . Furthermore, one of the three patients now has normal levels of CSF GAG, as do our dogs, presumably another sign of CNS improvement. In a related study, five transplanted children with MPS IH have shown improvement as assessed by serial Ruth Griffith's testing. This suggests that these children have not regressed as expected with untreated MPS IH (43). Findings in human marrow transplant recipients, coupled with the biochemical and ultrastructural findings in dogs, provide reasons to consider the possibility of neurologic improvement after transplantation therapy in metabolic disease. Whereas bone marrow transplantation has become much more routine for treatment of hematologic disease, the full potential in metabolic diseases, including those with neurologic involvement, may not yet have been realized. Because bone marrow transplantation is such a costly and potentially dangerous procedure, careful evaluation of its benefits versus risks must occur before it can be widely accepted as treatment for any metabolic disease.
